Other Routes of Protein and Peptide Delivery: Transdermal, Topical, Uterine, and Rectal - Challenges in Delivery of Therapeutic Genomics and Proteomics - page 661

[107] Sawyer TK. Peptidomimetic design and chemical approaches to peptide metabolism.
In: Taylor MD, Amidon GL, editors. Peptide based drug design: controlling transport
and metabolism. Washington, DC: American Chemical Society; 1995. p. 387-422.
[108] Friis GJ, Bundgaard H. Design and application of prodrugs. In: Krogsgaard-Larsen P,
Liljefors T, Madsen U, editors. A textbook of drug design and development. Amsterdam:
Harwood Academic Publishers; 1996. p. 351-85.
[109] Taylor MD. Improved passive oral drug delivery via prodrugs. Adv Drug Deliv Rev
1996;19:131-48.
[110] Bundgaard H. Means to enhance penetration: prodrugs as a means to improve the deliv-
ery of peptide drugs. Adv Drug Deliv Rev 1992;8:1-38.
[111] Oliyai R. Prodrugs of peptides and peptidomimetics for improved formulation and
delivery. Adv Drug Deliv Rev 1996;19:275-86.
[112] Bommannan D, Potts RO, Guy RH. Examination of the effect of ethanol on human stra-
tum corneum in vivo using infrared spectroscopy. J Control Release 1991;16:299-304.
[113] Spatola AF. Peptide backbone modifications: a structure-activity analysis of peptides
containing amide bond surrogates, conformational constraints, and related backbone
replacements. In: Weinstein B, editor. Chemistry and biochemistry of amino acids, pep-
tides, and proteins, vol. III. New York, NY: Marcel Dekker; 1983. p. 287-300.
[114] Christrup LL, Møss J, Steffansen B. Prodrugs, preservation of pharmaceutical products
to salt forms of drugs and absorption. In: Swarbrick J, Boylan JC, editors. Encyclopedia
of pharmaceutical technology. New York, NY: Marcel Dekker; 1996. p. 39-70.
[115] Barry BW. Mode of action of penetration enhancers in human skin. J Control Release
1987;6:85-97.
[116] Barry BW. Lipid-protein-partitioning theory of skin penetration enhancement. J Control
Release 1991;15:237-48.
[117] Walters KA. Penetration enhancers and their use in transdermal therapeutic systems.
In: Hadgraft J, Guy RH, editors. Transdermal drug delivery: developmental issues and
research initiatives. New York, NY: Marcel Dekker; 1989. p. 197-246.
[118] Pfister WR, Hsieh DST. Permeation enhancers compatible with transdermal drug deliv-
ery systems: part II: system design considerations. Med Device Technol 1990;1:28-33.
[119] Choi H, Flynn GL, Amidon GL. Transdermal delivery of bioactive peptides: the effect
of n -decylmethyl sulfoxide, pH, and inhibitors on enkephalin metabolism and transport.
Pharm Res 1990;7:1099-106.
[120] Chiang CH, Shao CH, Chen JL. Effects of pH, electric current, and enzyme inhibitors
on iontophoresis of delta sleep-inducing peptide. Drug Dev Ind Pharm 1998;24:431-8.
[121] Down JA, Harvey NG. Transdermal drug delivery. In: Guy RH, Hadgraft J, editors.
Minimally invasive systems for transdermal drug delivery, vol. 123. New York, NY:
Marcel Dekker; 2003. p. 327-60.
[122] Eppstein JA, Delcher HK, Hatch MR, McRae MS, Papp J, Woods TJ. Insulin infu-
sion via thermal micropores. Proc Int Symp Control Release Bioact Mater 2000;27:
1010-11.
[123] Svedman P, Lundin S, Svedman C. Administration of antidiuretic peptide (DDAVP) by
way of suction de-epithelialised skin. Lancet 1991;337:1506-9.
[124] Sarphie DF, Johnson B, Cormier M, Burkoth TL, Bellhouse BJ. Bioavailability follow-
ing transdermal powdered delivery (TPD) of radio labelled insulin to hairless guinea
pigs. J Control Release 1997;47:61-9.
[125] Banga A. Transdermal and topical delivery of therapeutic peptide and protein. In:
Therapeutic peptides and proteins: formulation, processing and delivery systems.
2nd ed. Florida: Taylor & Francis; 2006 p. 259-81.